4 completed, 1 recruiting, 1 unknown. 2 Not applicable, 2 Phase 3, 1 Early Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 2 |
| Phase 3 | 2 | Completed 2 |
| Early Phase 1 | 1 | Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow this drug Literature Review of Antimalarials trials Research Report on Antimalarials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chinese Rheumatism Biobank(CRB) Antimalarial with or without oral glucocorticosteroid - Lupus Erythematosus, Systemic | Recruiting | Chinese SLE Treatment And Research Group | 300 | 2025-02-10 | 2025-04-09 | |
| Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE Anifrolumab, Standard of Care - Systemic Lupus Erythematosus (SLE) | Early Phase 1 | Unknown | Oklahoma Medical Research Foundation | 20 | 2021-01-20 | 2023-03-22 |
| Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine Antimalarials, pyronaridine-artesunate, Antimalarials, Artemether + Lumefantrine - Malaria Fever, Plasmodium Falciparum Malaria | Phase 2 / Phase 3 | Completed | University of Ibadan | 172 | 2019-05-20 | 2022-04-07 |
| Mass Screening and Treatment for Reduction of Falciparum Malaria Ultrasensitive Rapid Diagnostic Test (URDT), Antimalarials - Plasmodium Falciparum Malaria | Not applicable | Completed | University of Oxford | 5542 | 2018-11-01 | 2024-03-27 |
| Hydroxychloroquine for Thrombosis Prevention and Antiphospholipid Antibody Reduction in Primary Antiphospholipid Syndrome Hydroxychloroquine - Antiphospholipid Syndrome | Not applicable | Completed | National and Kapodistrian University of Athens | 50 | 2013-01-15 | 2019-11-06 |
| A Study of LY2127399 in Participants With Systemic Lupus Erythematosus LY2127399, Placebo every 2 weeks, Placebo every 4 weeks - Systemic Lupus Erythematosus, Connective Tissue Disease | Phase 3 | Completed | Eli Lilly and Company | 1164 | 2010-12-01 | 2018-06-12 |
Lupus Erythematosus, Systemic (3) · Malaria, Falciparum (2) · Antiphospholipid Syndrome (1) · Autoimmune Diseases (1) · Connective Tissue Diseases (1) · Immune System Diseases (1) · Malaria (1)
Chinese SLE Treatment And Research Group (1) · Eli Lilly and Company (1) · National and Kapodistrian University of Athens (1) · Oklahoma Medical Research Foundation (1) · University of Ibadan (1) · University of Oxford (1)
Thailand (2) · United States (2) · Argentina (1) · Austria (1) · Belarus (1) · Bulgaria (1) · Canada (1) · Chile (1) · China (1) · Colombia (1) · Croatia (1) · Egypt (1) · Germany (1) · Greece (1) · Guatemala (1)
Catherine O Falade, MB.BS, MSc, FMCP, FWACP, MD (1) · Cristina Arriens, M.D. (1) · Joan T Merrill, M.D. (1) · Maria G Tektonidou, MD PhD (1)
PMID 26338095, PMID 27220348, PMID 27723281, PMID 29045736, PMID 31790472, PMID 35947992, PMID 37179349, PMID 38676311